Tornesp 40 PFS
Tornesp 40 PFS is a recombinant form of human erythropoietin used to treat anemia by stimulating red blood cell production. It increases the differentiation of progenitor cells to red blood cells, thus alleviating anemia associated with chronic kidney disease, chemotherapy, and certain HIV treatments.
Generic Name
Darbepoetin alfa Injection 40 mcg / 0.40 ml
Composition
Darbepoetin alfa Injection 40 mcg / 0.40 ml
Mode of Action
Darbepoetin alfa stimulates erythropoiesis by the same mechanism as endogenous erythropoietin. It binds to erythropoietin receptors (EPO-Rs) on hematopoietic cells, which results in the survival, differentiation, proliferation, and maturation of red blood cells. This increases RBCs and alleviates anemia.
Indications
Indicated for the treatment of anemia associated with renal transplants, chemotherapy, or certain HIV treatments.
Dosage
For Chronic Kidney Disease (CKD) Patients Not on Dialysis: Initial dose: 0.45 mcg/kg IV or subcutaneously once every 4 weeks.\nFor CKD Patients on Dialysis: Initial dose: 0.45 mcg/kg IV or subcutaneously once a week or 0.75 mcg/kg once every 2 weeks.\nFor Anemia Associated with Chemotherapy: Initial dose: 2.25 mcg/kg subcutaneously once a week or 500 mcg subcutaneously once every 3 weeks.
This information is for registered medical practitioners only. Consult your medical practitioner before consuming the product.